sellModerate cluster of 510b5-1 plan
Bruce Booth sold $45M of KYMR
director at Kymera Therapeutics, Inc.. 478,198 shares at an average of $94.72, traded Jun 17, 2026, filed Jun 22, 2026.
Warning score
40Value
$45M
478,198 shares
Holdings after
617,663
-4073% from before
From 52-week low
+139%
low $37.68, close $89.90
From 52-week high
-5%
high $95.03, as of Jun 17, 2026
Score components
- +15RoleDirector
- +25Trade size$45.3M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
KYMROct 9, 2026 · close 112.40
Since filing Jun 22, 2026: +13.0%SPY +4.9% · excess +8.2%
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001451612-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | MOption exercise Common Stock10b5-1 | +11,741 | $20.00 | $235k | 11,741 | Jun 22, 2026 |
| Jun 17, 2026 | SOpen-market sale Common Stock10b5-1 | -11,741 | $89.98 | $1.1M | 0 | Jun 22, 2026 |
| Jun 17, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -92,169 | $90.38 | $8.3M | 3,807,660 | Jun 22, 2026 |
| Jun 17, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -12,902 | $90.38 | $1.2M | 662,042 | Jun 22, 2026 |
| Jun 18, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -62,897 | $90.48 | $5.7M | 3,744,763 | Jun 22, 2026 |
| Jun 18, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -32,359 | $91.85 | $3.0M | 3,712,404 | Jun 22, 2026 |
| Jun 18, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -5,672 | $92.16 | $523k | 3,706,732 | Jun 22, 2026 |
| Jun 18, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -8,809 | $90.48 | $797k | 653,233 | Jun 22, 2026 |
| Jun 18, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -4,526 | $91.85 | $416k | 648,707 | Jun 22, 2026 |
| Jun 18, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -793 | $92.16 | $73k | 647,914 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -14,921 | $92.14 | $1.4M | 3,691,811 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,035 | $94.48 | $192k | 3,689,776 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -11,783 | $95.12 | $1.1M | 3,677,993 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -20,903 | $96.24 | $2.0M | 3,657,090 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -16,084 | $97.68 | $1.6M | 3,641,006 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -25,976 | $98.58 | $2.6M | 3,615,030 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -52,442 | $99.57 | $5.2M | 3,562,588 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -56,348 | $100.17 | $5.6M | 3,506,240 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,597 | $101.61 | $670k | 3,499,643 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -8,990 | $102.48 | $921k | 3,490,653 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,179 | $92.14 | $201k | 645,735 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -286 | $94.48 | $27k | 645,449 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,648 | $95.12 | $157k | 643,801 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,919 | $96.24 | $281k | 640,882 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,247 | $97.68 | $219k | 638,635 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,603 | $98.58 | $355k | 635,032 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -7,319 | $99.57 | $729k | 627,713 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -7,879 | $100.17 | $789k | 619,834 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -918 | $101.61 | $93k | 618,916 | Jun 22, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,253 | $102.48 | $128k | 617,663 | Jun 22, 2026 |
| Jun 17, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,741 | $0.00 | $0 | 28,127 | Jun 22, 2026 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 30Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $6.0M 50,000 shares | -7% | |
| 26Weak | Kymera Therapeutics, Inc. | Noah Goodman Chief Business Officer | $387k 3,389 shares | -7% | |
| 32Weak | Kymera Therapeutics, Inc. | Bruce N. Jacobs Chief Financial Officer | $8.9M 77,109 shares | -24% | |
| 35Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $9.2M 80,000 shares | -11% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $8.3M 76,650 shares | -3% | |
| 40Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $56M 513,245 shares | -18% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $3.4M 31,283 shares | -1% | |
| 75Notable | Kymera Therapeutics, Inc. | Bvf Partners L P/il director, other | $174M 1,630,658 shares | -58% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.